title: 3,5-Dicaffeoyl-4-malonylquinic acid reduced oxidative stress and inflammation in a experimental model of inflammatory bowel disease.
abstract: OBJECTIVE
  The aim of the present study was to examine the effects of 3,5-dicaffeoyl-4-malonylquinic acid (CA1), extract from Centella Asiatica, in rats subjected to experimental colitis.
  
  
  RESULTS
  Colitis was induced in rats by intracolonic instillation of dinitrobenzene sulphonic acid (DNBS). CA1 was administered daily orally (0.2 or 2 mg/kg). Four days after DNBS administration, treatment with CA1 significantly reduced the appearance of diarrhoea and the loss of body weight. This was associated with a significant reduction in colonic MPO activity. CA1 also reduced NF-kappaB activation, the pro-inflammatory cytokines release, the appearance of I-NOS, nitrotyrosine, PARP and proMMP-9 and -2 activity in the colon and reduced the up-regulation of ICAM-1 and the expression of P-Selectin.
  
  
  CONCLUSIONS
  The results of this study suggested that administration of CA1 may be beneficial for treatment of inflammatory bowel disease.
authors.affiliation: IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy.
authors.forename: Rosanna
authors.initials: R
authors.lastname: di Paola
authors.forename: Emanuela
authors.initials: E
authors.lastname: Esposito
authors.forename: Emanuela
authors.initials: E
authors.lastname: Mazzon
authors.forename: Rocco
authors.initials: R
authors.lastname: Caminiti
authors.forename: Roberto Dal
authors.initials: RD
authors.lastname: Toso
authors.forename: Giovanna
authors.initials: G
authors.lastname: Pressi
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cozzocrea
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002109:Caffeic Acids / Q000494:pharmacology* / Q000627:therapeutic use*; D002478:Cells, Cultured; D028041:Centella; D002726:Chlorogenic Acid / Q000031:analogs & derivatives; D003106:Colon / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D008954:Models, Biological; D018384:Oxidative Stress / Q000187:drug effects*; D010936:Plant Extracts; D011801:Quinic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D014315:Triterpenes / Q000494:pharmacology
chemical_list: C547821:3,5-dicaffeoyl-4-malonylquinic acid; D000893:Anti-Inflammatory Agents; D002109:Caffeic Acids; C526146:Centella asiatica extract; D010936:Plant Extracts; D014315:Triterpenes; D011801:Quinic Acid; D002726:Chlorogenic Acid